Profile Picture
  • All
  • Images
  • Videos
  • Maps
  • News
  • Shopping
  • Copilot
  • More
    • Flights
    • Travel
  • Notebook
  • Top stories
  • Sports
  • U.S.
  • Local
  • World
  • Science
  • Technology
  • Entertainment
  • Business
  • More
    Politics
Order byBest matchMost fresh
  • Past 24 hours
    • Any time
    • Past hour
    • Past 7 days
    • Past 30 days
The Lancet
2d

Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial

Copyright: © 2022 The Author(s). Published by Elsevier Ltd.

Some results have been hidden because they may be inaccessible to you

Show inaccessible results

Trending now

Judge blocks Trump's plan
Judge halts Trump fund
Pulls out of 'Freedom 250'
Maddox drops Pitt surname
Man held for threatening Kirk
Deadly I-95 bus crash
Hawaii triple murder arrest
ABC accuses Trump’s FCC
Kenya court suspends US plan
ICE agent arrested in Texas
To host America 250 special
Poison seller pleads guilty
8 arrested in school fire
US labels Brazil crime groups
WHO confirms Ebola recovery
MLB proposes salary cap
Families settle bridge suit
US sanctions Iran’s oil sales
Testifies behind closed doors
Trump meets with aides
LA House passes new map
Knocked out of French Open
3 climbers dead, 1 rescued
RU drone crashes in Romania
China crew back on Earth
Rescuers pull 1st person
Hit with new bribery charges
TX roller coaster malfunction
Ghana passes anti-LGBTQ bill
NJ Transit service resumes
Ex-Des Moines chief sentenced
  • Privacy
  • Terms